How emerging biotechs can enter the Chinese market and prosper
Small and emerging biotechs in the United States and Europe have long been wary of trying to enter the Chinese market, despite its vast potential. They’ve shied away due to changing regulatory and reimbursement policies, unreliable intellectual property protections, and fear that the Chinese government may favor domestic firms. But things have changed, and companies don’t need to be hesitant anymore.
Since 2015, a slew of economic and regulatory reforms have improved the Chinese market dynamics for foreign companies. In 2018, the Chinese State Council eliminated tariffs (of 6% to 10%) on all imported cancer drugs and slashed the value-added tax on them from 17% to 3%. In 2020, 28 new drugs from nondomestic companies were approved by the National Medical Products Administration (NMPA), faster and more dependably than before. In May 2021, China was reelected for a three-year term to the management committee of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, further aligning it with international regulatory standards.
Large international pharma companies often include China because of its market size, and many put it near the top of the list when sequencing global marketing submissions. But how can small and emerging foreign companies with limited resources gain a foothold in the Chinese market? Here are five approaches that help.
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Podcast
Leveraging people, processes and technology to deliver for biotech
Oct 1, 2024
Blog
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021
Blog
Three Ways Early-Stage Companies Can Attract Investors
Feb 3, 2022
Podcast
Funding Biotech Innovation: How to Attract Investors
Jan 18, 2022
Video
Biotech Showcase: Fireside Chat with Jamie Macdonald
Jan 3, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Blog
Master Protocol Trials: What Are the Elements of Success?
Dec 1, 2021
Case Study
Case Study Marketing Authorization Transfer
Nov 25, 2021
Case Study
Case Study Lifecycle maintenance
Nov 25, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Podcast
Leveraging people, processes and technology to deliver for biotech
Oct 1, 2024
Blog
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021
Blog
Three Ways Early-Stage Companies Can Attract Investors
Feb 3, 2022
Podcast
Funding Biotech Innovation: How to Attract Investors
Jan 18, 2022
Video
Biotech Showcase: Fireside Chat with Jamie Macdonald
Jan 3, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Blog
Master Protocol Trials: What Are the Elements of Success?
Dec 1, 2021
Case Study
Case Study Marketing Authorization Transfer
Nov 25, 2021
Case Study
Case Study Lifecycle maintenance
Nov 25, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021